RxCelerate is an outsourced drug discovery and development company, based in Cambridge, UK, dedicated to delivering scientific excellence to a global client base within the biotech and pharma sectors.

They offer a comprehensive suite of services including in silico design, antibody discovery, synthetic and medicinal chemistry, bioanalysis, in vitro and preclinical services, and project management. Clients also benefit from proprietary platforms such as RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse 'clinic-ready' antibodies, and ProQuant® for precise bottom-up proteomics.

RxCelerate operates a unique model, offering collaborative strategic thinking to help clients design and execute every aspect of their research and development plans, turning promising discoveries into potential novel therapeutics. With a focus on rapidly advancing clients to proof of concept, they have contributed to more than 25 clinical candidates, 14 of which have progressed to the clinic, while maintaining a 75% repeat business rate. Numerous biotech companies have benefitted from RxCelerate’s tailored support and resources to overcome the significant challenges of early-stage drug discovery.